INMD News and Press, InMode Ltd. From 07/20/22

InMode to Present at the Canaccord 42nd Annual Growth Conference PR Newswire YOKNEAM, Israel , July 20, 2022 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca ...

So far, 2022 has been an awful year for the stock market. We've seen really bad inflation, and many investors think a recession is imminent. Nonetheless, some companies are reporting surprisingly strong numbers. Here are three healthcare stocks that missed their guidance -- in the right...

In 2021, it seemed as if medical technology stocks could do no wrong. Shares of cosmetic sculpting device manufacturer InMode (NASDAQ: INMD) more than doubled as enthusiasm for all things new and medically related reached a fever pitch. Shares of InMode have tanked 72% since the...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ArtemisDiana/Shutterstock It’s not every day that InMode (NASDAQ: INMD ) stock trends in the financial news. However, today’s a special day for the medical device company. As INMD stock shoot...

Gainers: Greenwich LifeSciences ( GLSI ) +41% . Histogen ( HSTO ) +37% . Oramed Pharmaceuticals ( ORMP ) +25% . InMode ( INMD ) +13% . Annexon ( ANNX ) +11% . Losers: Can-Fite BioPharma ( CANF ) -11% . Arc...

InMode ( NASDAQ: INMD ) expects Q2 revenue in the range of $113M - $113.3M vs. consensus of $103.01M and Non-GAAP diluted EPS in the range of $0.57 - $0.58 vs. consensus of $0.51. Q2 Non-GAAP gross margin to be in the range of 8...

InMode Expects Record Second Quarter 2022 Financial Results, Revenue Between $113.0-$113.3M, Increasing Full Year 2022 Revenue Guidance to $425-$435M PR Newswire Conference call to be held on Thursday, July 28, 2022 , at 8:30 a.m. Eastern Time YOKNEAM, Isra...

InMode is trading for a trough valuation, similar to the COVID panic low. The chart looks very bullish from the perspective that a bottom is likely in. The stock could double on a valuation reset alone. For further details see: InMode: Asymmetrical Reward Opportunity For...

InMode has generally been a great success story since its public offering. After a huge boom in 2021 and subsequent bust, valuations look very compelling again. While some concerns remain, the overall valuation argument prevails here. For further details see: InMode: Pre...

InMode (NASDAQ: INMD) is proof that there isn't always a trade-off between stocks with great value and those with tremendous growth potential. This medical device maker has everything you'd expect from a value stock -- a low valuation, repeatable business model, and cost-sensitive m...